Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
August 12, 2019Targovax ASA: Announcement of second quarter and first half results 2019
-
July 31, 2019Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
-
July 15, 2019Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
-
July 8, 2019Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma